VaxGen fails to meet deadlines and loses $900 million deal with the U.S. And, it's not just the vaccine that's in trouble but the whole bio-defense program it's part of, Project Bioshield. Helen Palmer reports.
Pfizer halted development of its new cholesterol drug following unexpected deaths during test trials. It's a huge blow to the drugmaker, which needs a blockbuster with Lipitor's patent set to expire in 5 years. Helen Palmer reports.